Prescribing of SGLT2 inhibitors in primary care: a qualitative study of General Practitioners and Endocrinologists
In 2015, the EMPA-REG OUTCOME trial reported that treatment with the sodium-glucose cotransporter 2 (SGLT2) inhibitor, empagliflozin, significantly reduced the risk of the primary composite outcome – death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke in patients with type 2 diabetes at high cardiovascular risk [1]. Since that landmark trial, many other large randomised controlled trials (RCTs) have confirmed the cardiovascular (particularly with respect to he art failure) and renal benefits of this drug class [2–7].
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Tamara Y. Milder, Sophie L. Stocker, Melissa Baysari, Richard O. Day, Jerry R. Greenfield Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Heart | Heart Attack | Jardiance | Primary Care | SGLT2 Inhibitors | Sodium | Stroke | Study